TriSalus Life Sciences, Inc.
TLSI
$5.73
$0.081.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -323.64% | 44.92% | 67.23% | 62.91% | -2,304.79% |
| Total Depreciation and Amortization | 14.20% | -12.89% | 3.19% | -3.09% | 24.36% |
| Total Amortization of Deferred Charges | 6.59% | -37.45% | -- | -- | -- |
| Total Other Non-Cash Items | 163.13% | -77.99% | -219.80% | -88.16% | 242.44% |
| Change in Net Operating Assets | 114.81% | 50.58% | -1,220.91% | -112.38% | 184.21% |
| Cash from Operations | 47.39% | 19.18% | -23.51% | -18.42% | 57.64% |
| Capital Expenditure | 70.41% | -181.67% | 9.09% | 82.26% | -108.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 207.07% |
| Cash from Investing | 70.41% | -181.67% | 9.09% | 82.26% | 66.55% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | 13.64% | -4.76% | 4.55% | 0.00% | 0.00% |
| Issuance of Common Stock | -48.45% | 62.05% | 14.58% | 3,603.53% | 203.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -100.06% |
| Cash from Financing | -48.58% | -77.60% | 731.51% | 7,169.77% | -99.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.79% | -141.51% | 260.25% | 17.87% | -154.39% |